- জেনেরিক নাম
- Sacubitril + Valsartan
- শক্তি
- 97 mg + 103 mg
- ডোজ ফর্ম
- Tablet
- প্রস্তুতকারক
- Opsonin Pharma Limited
Arnivas 200 Tablet
Arnivas 200 97 mg + 103 mg Tablet সম্পর্কে
বাংলাদেশে Arnivas 200 97 mg + 103 mg Tablet ট্যাবলেট হিসেবে পাওয়া যায়; এতে Sacubitril + Valsartan আছে (৯৭ mg + ১০৩ mg)। এটি তৈরি করে Opsonin Pharma Limited। Arnivas 200-এর সাথে Sacubitril + Valsartan-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।
Sacubitril + Valsartan-এর ২৫টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Arnis 24 mg+26 mg Tablet-এর, প্রতি ইউনিট ৳ ৩৫.০০।
Arnivas 200 97 mg + 103 mg Tablet কী?
Arnivas 200 97 mg + 103 mg tablet is a medicine made by Opsonin Pharma Limited. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. It is used in adults with long-term heart failure and reduced ejection fraction, and in children aged one year and older with symptomatic heart failure. The dose and course are decided by the doctor.
Arnivas 200-এর ব্যবহার
It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Only a qualified doctor can decide if it is suitable for a particular patient. Your doctor will decide if it is suitable for you or your child.
Arnivas 200 কীভাবে ব্যবহার করবেন
The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet with water. Arnivas 200 is taken by mouth. If a dose is missed, ask the doctor or pharmacist for advice. If you miss a dose, ask your doctor or pharmacist what to do. Do not change the dose or stop taking it without speaking to your doctor.
Arnivas 200-এর পার্শ্বপ্রতিক্রিয়া
Common side effects include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough and dizziness. Your doctor may check your kidney function and potassium levels during treatment. Low blood pressure may cause dizziness or fainting, especially when standing up quickly. Tell your doctor straight away if you have trouble breathing, swelling, or feel very dizzy or faint. Tell your doctor if any side effect bothers you or does not go away.
সতর্কতা ও নিরাপত্তা
Pregnancy and breastfeeding: ask the doctor before use. It is not recommended in severe liver impairment. This medicine is not recommended during pregnancy because it may harm the unborn baby. Tell your doctor about kidney or liver problems, low blood pressure, or other medicines you take, including potassium-sparing diuretics, NSAIDs and lithium.
সাধারণ প্রশ্ন
What is Arnivas 200 used for?
It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Only a qualified doctor can decide if it is suitable for a particular patient.
How should I take Arnivas 200?
The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet with water.
What are the side effects of Arnivas 200?
Common side effects include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough and dizziness. Your doctor may check your kidney function and potassium levels during treatment.
Is Arnivas 200 safe for everyone?
Pregnancy and breastfeeding: ask the doctor before use. It is not recommended in severe liver impairment.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
This is indicated:- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ... Read more
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
ফার্মাকোলজি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Recommended Dose Titration-
Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
This combination is contraindicated:- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
সতর্কতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.বিকল্প ব্র্যান্ড: Sacubitril + Valsartan
একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।